Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by mercedesmanon Oct 27, 2022 2:08pm
154 Views
Post# 35053816

RE:44 Patients Since Study Start Date of October 17, 2019

RE:44 Patients Since Study Start Date of October 17, 2019
BayStreetWild wrote: At a cost of $30M+ CAD.

let that sink in.



Or another way to look at it might be....

Most drugs/new treatments now cost > $ 1B USD to bring to market.  Most of that is R&D, Trials, etc..  (look it up)

It's amazing to think that the only new treament for Severe Sepsis in 30 years, an affliction that kills about 10 million people worldwide EACH YEAR, may be had for only about $ 100 - $ 125M  CAD $.   And that's with no other viable treatment options (except antibiotics).   I mostly credit Dr. Walker for his foresight and overall cost control.  I blame the financiers and advisors for not telling the story properly sooner, and thereby lowering the dilution to long time holders.

MM
<< Previous
Bullboard Posts
Next >>